David Meek, departing Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)
August 8, 2023 05:20 PM EDTUpdated August 9, 07:31 AM
People
Financing

Mi­rati an­nounces CEO res­ig­na­tion, then a $300M pub­lic of­fer­ing af­ter dis­clos­ing clin­i­cal plans

Kyle LaHucik

Senior Reporter

David Meek, the CEO of Mi­rati Ther­a­peu­tics, has re­signed from the biotech and its board, the San Diego drug de­vel­op­er said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times